Increased Plasma PCSK9 Levels Are Associated with Reduced Endotoxin Clearance and the Development of Acute Organ Failures during Sepsis

Journal of Innate Immunity

Volumn 8, Issue 2, 2016, Pages 211-220

  Boyd, John H ^a   Fjell, Christopher D ^a   Russell, James A ^a   Sirounis, Demetrios ^a   Cirstea, Mihai S ^a   Walley, Keith R ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Lipids; PCSK9; Sepsis

Indexed keywords

CHOLESTEROL; ESCHERICHIA COLI ENDOTOXIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; KEXIN; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; SUBTILISIN; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ENDOTOXIN; PCSK9 PROTEIN, HUMAN; PROPROTEIN CONVERTASE 9;

ACUTE HEART FAILURE; ACUTE RESPIRATORY FAILURE; ADULT; ARTICLE; CHOLESTEROL BLOOD LEVEL; CLEARANCE; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; HUMAN; HUMAN CELL; LIPID BLOOD LEVEL; LIVER CELL; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; SEPSIS; TRIACYLGLYCEROL BLOOD LEVEL; BLOOD; CELL LINE; IMMUNOLOGY; META ANALYSIS; METABOLISM; MULTIPLE ORGAN FAILURE;

CELL LINE; ENDOTOXINS; FEMALE; HEPATOCYTES; HUMANS; MALE; MULTIPLE ORGAN FAILURE; PROPROTEIN CONVERTASE 9; SEPSIS;

EID: 84954410240     PISSN: 1662811X     EISSN: 16628128     Source Type: Journal    
DOI: 10.1159/000442976     Document Type: Article

References (42)

1. Walley KR, Thain KR, Russell JA, Reilly MP, Meyer NJ, Ferguson JF, Christie JD, Nakada TA, Fjell CD, Thair SA, et al. PCSK9 is a critical regulator of the innate immune response and septic shock outcome. Science Transl Med 2014;6:258ra143.
2. Stein EA, Raal FJ: Insights into PCSK9, low-density lipoprotein receptor, and low-density lipoprotein cholesterol metabolism: of mice and man. Circulation 2013;127:2372-2374.
3. Fraunberger P, Schaefer S, Werdan K, Walli AK, Seidel D: Reduction of circulating cholesterol and apolipoprotein levels during sepsis. Clin Chem Lab Med 1999;37:357-362.
4. Chiarla C, Giovannini I, Siegel JH: The relationship between plasma cholesterol, amino acids and acute phase proteins in sepsis. Amino Acids 2004;27:97-100.
5. Chien JY, Jerng JS, Yu CJ, Yang PC: Low serum level of high-density lipoprotein cholesterol is a poor prognostic factor for severe sepsis. Crit Care Med 2005;33:1688-1693.
6. Shor R, Wainstein J, Oz D, Boaz M, Matas Z, Fux A, Halabe A: Low serum LDL cholesterol levels and the risk of fever, sepsis, and malignancy. Ann Clin Lab Sci 2007;37:343-348.
7. Lagrost L, Girard C, Grosjean S, Masson D, Deckert V, Gautier T, Debomy F, Vinault S, Jeannin A, Labbe J, et al. Low preoperative cholesterol level is a risk factor of sepsis and poor clinical outcome in patients undergoing cardiac surgery with cardiopulmonary bypass. Crit Care Med 2014;42:1065-1073.
8. Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, Hochman JS, Krumholz HM, Kushner FG, Lamas GA, et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction; a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1999 Guidelines for the Management of Patients with Acute Myocardial Infarction). J Am Coll Cardiol 2004;44:E1-E211.
9. Feingold KR, Moser AH, Shigenaga JK, Patzek SM, Grunfeld C: Inflammation stimulates the expression of PCSK9. Biochem Biophys Res Commun 2008;374:341-344.
10. Almontashiri NA, Vilmundarson RO, Ghasemzadeh N, Dandona S, Roberts R, Quyyumi AA, Chen HH, Stewart AF: Plasma PCSK9 levels are elevated with acute myocardial infarction in two independent retrospective angiographic studies. PLoS One 2014;9:e106294.
11. Arsenault BJ, Pelletier-Beaumont E, Almeras N, Tremblay A, Poirier P, Bergeron J, Despres JP: PCSK9 levels in abdominally obese men: association with cardiometabolic risk profile and effects of a one-year lifestyle modification program. Atherosclerosis 2014;236:321-326.
12. Awan Z, Dubuc G, Faraj M, Dufour R, Seidah NG, Davignon J, Rabasa-Lhoret R, Baass A: The effect of insulin on circulating PCSK9 in postmenopausal obese women. Clin Biochem 2014;47:1033-1039.
13. Awan Z, Seidah NG, MacFadyen JG, Benjannet S, Chasman DI, Ridker PM, Genest J: Rosuvastatin, proprotein convertase subtilisin/kexin type 9 concentrations, and LDL cholesterol response: the JUPITER trial. Clin Chem 2012;58:183-189.
14. Berthold HK, Seidah NG, Benjannet S, Gouni-Berthold I: Evidence from a randomized trial that simvastatin, but not ezetimibe, upregulates circulating PCSK9 levels. PLoS One 2013;8:e60095.
15. Blom DJ, Hala T, Bolognese M, Lillestol MJ, Toth PD, Burgess L, Ceska R, Roth E, Koren MJ, Ballantyne CM, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014;370:1809-1819.
16. Costet P, Hoffmann MM, Cariou B, Guyomarc'h Delasalle B, Konrad T, Winkler K: Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients. Atherosclerosis 2010;212:246-251.
17. Li S, Guo YL, Xu RX, Zhang Y, Zhu CG, Sun J, Qing P, Wu NQ, Jiang LX, Li JJ: Association of plasma PCSK9 levels with white blood cell count and its subsets in patients with stable coronary artery disease. Atherosclerosis 2014;234:441-445.
18. Li S, Zhu CG, Guo YL, Xu RX, Zhang Y, Sun J, Li JJ: The relationship between the plasma PCSK9 levels and platelet indices in patients with stable coronary artery disease. J Atheroscler Thromb 2015;22:76-84.
19. Noguchi T, Kobayashi J, Yagi K, Nohara A, Yamaaki N, Sugihara M, Ito N, Oka R, Kawashiri MA, Tada H, et al. Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study. Atherosclerosis 2011;217:165-170.
20. Raal F, Panz V, Immelman A, Pilcher G: Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy. J Am Heart Assoc 2013;2:e000028.
21. Taylor BA, Panza G, Pescatello LS, Chipkin S, Gipe D, Shao W, White CM, Thompson PD: Serum PCSK9 levels distinguish individuals who do not respond to high-dose statin therapy with the expected reduction in LDL-C. J Lipids 2014;2014:140723.
22. Zhang Y, Zhu CG, Xu RX, Li S, Guo YL, Sun J, Li JJ: Relation of circulating PCSK9 concentration to fibrinogen in patients with stable coronary artery disease. J Clin Lipidol 2014;8:494-500.
23. Kellum JA, Lameire N: Diagnosis, evaluation, and management of acute kidney injury: a KDIGO summary (part 1). Crit Care 2013;17:204.
24. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, Levin A: Acute kidney injury network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11:R31.
25. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P: Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 2004;8:R204-R212.
26. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, Holmes CL, Mehta S, Granton JT, Storms MM, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008;358:877-887.
27. Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH: Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med 2014;189:1075-1081.
28. Wong HR, Lindsell CJ, Pettila V, Meyer NJ, Thair SA, Karlsson S, Russell JA, Fjell CD, Boyd JH, Ruokonen E, et al. A multibiomarker-based outcome risk stratification model for adult septic shock. Crit Care Med 2014;42:781-789.
29. Padkin A, Goldfrad C, Brady AR, Young D, Black N, Rowan K: Epidemiology of severe sepsis occurring in the first 24 h in intensive care units in England, Wales, and Northern Ireland. Crit Care Med 2003;31:2332-2338.
30. Horton JD, Cohen JC, Hobbs HH: Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci 2007;32:71-77.
31. Benjannet S, Rhainds D, Essalmani R, Mayne J, Wickham L, Jin W, Asselin MC, Hamelin J, Varret M, Allard D, et al. NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol. J Biol Chem 2004;279:48865-48875.
32. Cunningham D, Danley DE, Geoghegan KF, Griffor MC, Hawkins JL, Subashi TA, Varghese AH, Ammirati MJ, Culp JS, Hoth LR, et al. Structural and biophysical studies of PCSK9 and its mutants linked to familial hypercholesterolemia. Nat Struct Mol Biol 2007;14:413-419.
33. Zhang DW, Lagace TA, Garuti R, Zhao Z, McDonald M, Horton JD, Cohen JC, Hobbs HH: Binding of proprotein convertase subtilisin/kexin type 9 to epidermal growth factor-like repeat A of low density lipoprotein receptor decreases receptor recycling and increases degradation. J Biol Chem 2007;282:18602-18612.
34. Tveten K, Strom TB, Berge KE, Leren TP: CSK9-mediated degradation of the LDL receptor generates a 17 kDa C-terminal LDL receptor fragment. J Lipid Res 2013;54:1560-1566.
35. Stein EA, Mellis S, Yancopoulos GD, Stahl N, Logan D, Smith WB, Lisbon E, Gutierrez M, Webb C, Wu R, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012;366:1108-1118.
36. Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH: Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N Engl J Med 2006;354:1264-1272.
37. Musunuru K, Lettre G, Young T, Farlow DN, Pirruccello JP, Ejebe KG, Keating BJ, Yang Q, Chen MH, Lapchyk N, et al. Candidate gene association resource (CARe): design, methods, and proof of concept. Circ Cardiovasc Genet 2010;3:267-275.
38. Kathiresan S, Voight BF, Purcell S, Musunuru K, Ardissino D, Mannucci PM, Anand S, Engert JC, Samani NJ, Schunkert H, et al. Genome-wide association of early-onset myocardial infarction with single nucleotide polymorphisms and copy number variants. Nat Genet 2009;41:334-341.
39. King A: Lipids: antibodies against PCSK9-a new era of therapy. Nat Rev Cardiol 2013;10:1.
40. Le Bras M, Roquilly A, Deckert V, Langhi C, Feuillet F, Sebille V, Mahe PJ, Bach K, Masson D, Lagrost L, et al. Plasma PCSK9 is a late biomarker of severity in patients with severe trauma injury. J Clin Endocrinol Metab 2013;98:E732-E736.
41. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, Sevransky JE, Sprung CL, Douglas IS, Jaeschke R, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med 2013;41:580-637.
42. Cruz DN, Antonelli M, Fumagalli R, Foltran F, Brienza N, Donati A, Malcangi V, Petrini F, Volta G, Bobbio Pallavicini FM, et al. Early use of polymyxin B hemoperfusion in abdominal septic shock: the EUPHAS randomized controlled trial. JAMA 2009;301:2445-2452.